Radiotherapy timing in the treatment of limited-stage small cell lung cancer: The impact of thoracic and brain irradiation on survival

Vieri Scotti, Icro Meattini, Ciro Franzese, Calogero Saieva, Silvia Bertocci, Fiammetta Meacci, Ilaria Furfaro, Daniele Scartoni, Sara Cecchini, Isacco Desideri, Katia Ferrari, Alessio Bruni, Carla De Luca Cardillo, Paolo Bastiani, Benedetta Agresti, Monica Mangoni, Lorenzo Livi, Giampaolo Biti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aims and background. Small cell lung cancer is an aggressive histologic subtype of lung cancer in which the role of chemotherapy and radiotherapy has been well established in limited-stage disease. We retrospectively reviewed a series of limitedstage small cell lung cancers treated with chemotherapy and thoracic and brain radiotherapy. Methods and study design. A total of 124 patients affected by limited-stage small cell lung cancer has been treated over 10 years in our Institute. Fifty-three patients (42.8%) had concomitant radio-chemotherapy treatment and 71 patients (57.2%) a sequential treatment. Eighty-eight patients (70.9%) underwent an association of a platinum-derived drug (cisplatinum or carboplatinum) and etoposide. Prophylactic cranial irradiation was planned in all patients with histologically proven complete response to primary radio-chemotherapy. Results. With a mean follow-up of 2.2 years, complete response was obtained in 50.8% of cases. We found a significant difference between different radio-chemotherapy association approaches (P = 0.007): percentages of overall survival were respectively 10.0%, 12.9% and 5.6% in early, late concomitant and sequential radiochemotherapy timing. Cranial prophylaxis did not seem to influence overall survival (P = 0.21) or disease-free survival for local relapse (P = 0.34). Conclusions. Concomitant radio-chemotherapy is the best approach according to our experience. Our results show a benefit of prophylactic cranial irradiation in distant metastasis-free survival. Copyright - Il Pensiero Scientifico Editore.

Original languageEnglish
Pages (from-to)289-295
Number of pages7
JournalTumori
Volume100
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Small Cell Lung Carcinoma
Radiotherapy
Thorax
Radio
Drug Therapy
Survival
Brain
Cranial Irradiation
Therapeutics
Chemoradiotherapy
Etoposide
Platinum
Disease-Free Survival
Lung Neoplasms
Neoplasm Metastasis
Recurrence
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Limited stage
  • Prophylactic cranial irradiation
  • Radiotherapy
  • Small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Radiotherapy timing in the treatment of limited-stage small cell lung cancer : The impact of thoracic and brain irradiation on survival. / Scotti, Vieri; Meattini, Icro; Franzese, Ciro; Saieva, Calogero; Bertocci, Silvia; Meacci, Fiammetta; Furfaro, Ilaria; Scartoni, Daniele; Cecchini, Sara; Desideri, Isacco; Ferrari, Katia; Bruni, Alessio; Cardillo, Carla De Luca; Bastiani, Paolo; Agresti, Benedetta; Mangoni, Monica; Livi, Lorenzo; Biti, Giampaolo.

In: Tumori, Vol. 100, No. 3, 2014, p. 289-295.

Research output: Contribution to journalArticle

Scotti, V, Meattini, I, Franzese, C, Saieva, C, Bertocci, S, Meacci, F, Furfaro, I, Scartoni, D, Cecchini, S, Desideri, I, Ferrari, K, Bruni, A, Cardillo, CDL, Bastiani, P, Agresti, B, Mangoni, M, Livi, L & Biti, G 2014, 'Radiotherapy timing in the treatment of limited-stage small cell lung cancer: The impact of thoracic and brain irradiation on survival', Tumori, vol. 100, no. 3, pp. 289-295. https://doi.org/10.1700/1578.17206
Scotti, Vieri ; Meattini, Icro ; Franzese, Ciro ; Saieva, Calogero ; Bertocci, Silvia ; Meacci, Fiammetta ; Furfaro, Ilaria ; Scartoni, Daniele ; Cecchini, Sara ; Desideri, Isacco ; Ferrari, Katia ; Bruni, Alessio ; Cardillo, Carla De Luca ; Bastiani, Paolo ; Agresti, Benedetta ; Mangoni, Monica ; Livi, Lorenzo ; Biti, Giampaolo. / Radiotherapy timing in the treatment of limited-stage small cell lung cancer : The impact of thoracic and brain irradiation on survival. In: Tumori. 2014 ; Vol. 100, No. 3. pp. 289-295.
@article{029145efc91c4b8281e921e74d110ec1,
title = "Radiotherapy timing in the treatment of limited-stage small cell lung cancer: The impact of thoracic and brain irradiation on survival",
abstract = "Aims and background. Small cell lung cancer is an aggressive histologic subtype of lung cancer in which the role of chemotherapy and radiotherapy has been well established in limited-stage disease. We retrospectively reviewed a series of limitedstage small cell lung cancers treated with chemotherapy and thoracic and brain radiotherapy. Methods and study design. A total of 124 patients affected by limited-stage small cell lung cancer has been treated over 10 years in our Institute. Fifty-three patients (42.8{\%}) had concomitant radio-chemotherapy treatment and 71 patients (57.2{\%}) a sequential treatment. Eighty-eight patients (70.9{\%}) underwent an association of a platinum-derived drug (cisplatinum or carboplatinum) and etoposide. Prophylactic cranial irradiation was planned in all patients with histologically proven complete response to primary radio-chemotherapy. Results. With a mean follow-up of 2.2 years, complete response was obtained in 50.8{\%} of cases. We found a significant difference between different radio-chemotherapy association approaches (P = 0.007): percentages of overall survival were respectively 10.0{\%}, 12.9{\%} and 5.6{\%} in early, late concomitant and sequential radiochemotherapy timing. Cranial prophylaxis did not seem to influence overall survival (P = 0.21) or disease-free survival for local relapse (P = 0.34). Conclusions. Concomitant radio-chemotherapy is the best approach according to our experience. Our results show a benefit of prophylactic cranial irradiation in distant metastasis-free survival. Copyright - Il Pensiero Scientifico Editore.",
keywords = "Chemotherapy, Limited stage, Prophylactic cranial irradiation, Radiotherapy, Small cell lung cancer",
author = "Vieri Scotti and Icro Meattini and Ciro Franzese and Calogero Saieva and Silvia Bertocci and Fiammetta Meacci and Ilaria Furfaro and Daniele Scartoni and Sara Cecchini and Isacco Desideri and Katia Ferrari and Alessio Bruni and Cardillo, {Carla De Luca} and Paolo Bastiani and Benedetta Agresti and Monica Mangoni and Lorenzo Livi and Giampaolo Biti",
year = "2014",
doi = "10.1700/1578.17206",
language = "English",
volume = "100",
pages = "289--295",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Radiotherapy timing in the treatment of limited-stage small cell lung cancer

T2 - The impact of thoracic and brain irradiation on survival

AU - Scotti, Vieri

AU - Meattini, Icro

AU - Franzese, Ciro

AU - Saieva, Calogero

AU - Bertocci, Silvia

AU - Meacci, Fiammetta

AU - Furfaro, Ilaria

AU - Scartoni, Daniele

AU - Cecchini, Sara

AU - Desideri, Isacco

AU - Ferrari, Katia

AU - Bruni, Alessio

AU - Cardillo, Carla De Luca

AU - Bastiani, Paolo

AU - Agresti, Benedetta

AU - Mangoni, Monica

AU - Livi, Lorenzo

AU - Biti, Giampaolo

PY - 2014

Y1 - 2014

N2 - Aims and background. Small cell lung cancer is an aggressive histologic subtype of lung cancer in which the role of chemotherapy and radiotherapy has been well established in limited-stage disease. We retrospectively reviewed a series of limitedstage small cell lung cancers treated with chemotherapy and thoracic and brain radiotherapy. Methods and study design. A total of 124 patients affected by limited-stage small cell lung cancer has been treated over 10 years in our Institute. Fifty-three patients (42.8%) had concomitant radio-chemotherapy treatment and 71 patients (57.2%) a sequential treatment. Eighty-eight patients (70.9%) underwent an association of a platinum-derived drug (cisplatinum or carboplatinum) and etoposide. Prophylactic cranial irradiation was planned in all patients with histologically proven complete response to primary radio-chemotherapy. Results. With a mean follow-up of 2.2 years, complete response was obtained in 50.8% of cases. We found a significant difference between different radio-chemotherapy association approaches (P = 0.007): percentages of overall survival were respectively 10.0%, 12.9% and 5.6% in early, late concomitant and sequential radiochemotherapy timing. Cranial prophylaxis did not seem to influence overall survival (P = 0.21) or disease-free survival for local relapse (P = 0.34). Conclusions. Concomitant radio-chemotherapy is the best approach according to our experience. Our results show a benefit of prophylactic cranial irradiation in distant metastasis-free survival. Copyright - Il Pensiero Scientifico Editore.

AB - Aims and background. Small cell lung cancer is an aggressive histologic subtype of lung cancer in which the role of chemotherapy and radiotherapy has been well established in limited-stage disease. We retrospectively reviewed a series of limitedstage small cell lung cancers treated with chemotherapy and thoracic and brain radiotherapy. Methods and study design. A total of 124 patients affected by limited-stage small cell lung cancer has been treated over 10 years in our Institute. Fifty-three patients (42.8%) had concomitant radio-chemotherapy treatment and 71 patients (57.2%) a sequential treatment. Eighty-eight patients (70.9%) underwent an association of a platinum-derived drug (cisplatinum or carboplatinum) and etoposide. Prophylactic cranial irradiation was planned in all patients with histologically proven complete response to primary radio-chemotherapy. Results. With a mean follow-up of 2.2 years, complete response was obtained in 50.8% of cases. We found a significant difference between different radio-chemotherapy association approaches (P = 0.007): percentages of overall survival were respectively 10.0%, 12.9% and 5.6% in early, late concomitant and sequential radiochemotherapy timing. Cranial prophylaxis did not seem to influence overall survival (P = 0.21) or disease-free survival for local relapse (P = 0.34). Conclusions. Concomitant radio-chemotherapy is the best approach according to our experience. Our results show a benefit of prophylactic cranial irradiation in distant metastasis-free survival. Copyright - Il Pensiero Scientifico Editore.

KW - Chemotherapy

KW - Limited stage

KW - Prophylactic cranial irradiation

KW - Radiotherapy

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84921675152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921675152&partnerID=8YFLogxK

U2 - 10.1700/1578.17206

DO - 10.1700/1578.17206

M3 - Article

C2 - 25076240

AN - SCOPUS:84921675152

VL - 100

SP - 289

EP - 295

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 3

ER -